

Special Issue

Molecular Research on Pancreatic Cancer: Current Trends and New Perspectives

Message from the Guest Editors

Over the last decade we observed a significant improvement in the prognosis of many solid tumors thanks to the advent of immunotherapy and targeted therapies expanding the therapeutic opportunities for cancer patients and realizing the promise of personalized medicine. Despite these advances, pancreatic cancer remains an incurable disease, where immune-checkpoint inhibitors and targeted drugs are generally not efficacious. For this reason, it is still perceived as a hopeless disease by both patients and physicians. More than 80% of pancreatic cancer patients are diagnosed when the tumor is in contact with vascular structures or when distant metastases are present, and thus surgical excision is not indicated. For these patients, the standard of care is palliative chemotherapy, with a median overall survival of 11 months. Since 2011, three independent studies by Collison, Moffit and Bailey identified different pancreatic cancer subtypes based on gene expression profiles, suggesting that pancreatic cancer is not a unique entity, but should be regarded as a collection of different diseases.

Guest Editors

Dr. Cinzia Bagalà

Faculty of Medicine and Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Dr. Marta Chiaravalli

1. Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore, 00168 Rome, Italy
2. Medical Oncology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/141835

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).